Core Viewpoint - NeuroOne Medical Technologies Corporation is set to release its financial results for the fiscal second quarter ending March 31, 2025, on May 13, 2025, before market open [1] Group 1: Financial Results Announcement - The financial results will be discussed in an investor conference call and webcast scheduled for May 13, 2025, at 8:30 a.m. Eastern time [2] - Participants can join the call using specific dial-in numbers and access codes provided [2] Group 2: Company Overview - NeuroOne is focused on developing minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation for patients with neurological disorders [4] - The company aims to improve patient outcomes and reduce procedural costs, with potential applications in various areas including depression, mood disorders, and high blood pressure [4]

Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous ...

Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. Dear Shareholders, In recent months, NeuroOne has achieved sever ...

Core Insights - NeuroOne Medical Technologies Corporation has developed the OneRF® Ablation System, which has successfully treated a pediatric epilepsy patient, Clara Fuller, who previously experienced up to 10 seizures per night, resulting in her being completely seizure-free post-treatment [1][2][3] Company Overview - NeuroOne is focused on improving surgical care options for patients with neurological disorders, including epilepsy, Parkinson's disease, and chronic pain, through minimally invasive and high-definition solutions [4] - The company is exploring additional applications for its technology in areas such as depression, mood disorders, and pain management [4] Technology Impact - The OneRF® technology allows for minimally invasive radiofrequency ablation of seizure-causing brain tissue, significantly improving the quality of life for patients like Clara [2][3] - The successful treatment of Clara Fuller highlights the potential of the OneRF® platform to advance care for patients with debilitating neurological conditions [3]

Core Viewpoint - NeuroOne Medical Technologies Corporation has announced a public offering of 16,000,000 shares of common stock at a price of $0.50 per share, aiming to raise approximately $8,000,000 in gross proceeds for general working capital purposes [1][3]. Group 1: Offering Details - The offering consists entirely of shares sold by the Company, with an additional 45-day option for the underwriter to purchase up to 2,400,000 additional shares at the public offering price [2]. - The expected gross proceeds from the offering, before deductions, are $8,000,000, with the closing anticipated on or about April 7, 2025, subject to customary conditions [3]. Group 2: Regulatory Information - The shares will be issued under a shelf registration statement on Form S-3, which was declared effective by the SEC on August 16, 2024 [4]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [4]. Group 3: Contact Information - For further inquiries, contact information for the MZ Group is provided, including a phone number and email address [7][8].

Company Overview - NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients with neurological disorders [1][2]. Proposed Offering - The company has commenced a proposed underwritten registered public offering of shares of its common stock, with all shares to be sold by the company [1][2]. - The company intends to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares sold in the offering [2]. - The offering is subject to market and other conditions, with no assurance on the completion, size, or terms of the offering [2]. Underwriter Information - Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the proposed offering [3]. Regulatory Compliance - The proposed offering is made pursuant to a shelf registration statement on Form S-3, which was declared effective by the U.S. Securities and Exchange Commission on August 16, 2024 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the SEC's website [4].

Core Insights - NeuroOne Medical Technologies Corporation is focused on improving surgical care for patients with neurological disorders, particularly epilepsy, through innovative technology [1][5] - The OneRF® Ablation System is a significant advancement in epilepsy treatment, being the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [3][4] Company Overview - NeuroOne is developing minimally invasive solutions for EEG recording, brain stimulation, and ablation for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5] - The company aims to enhance patient outcomes and reduce procedural costs while exploring applications in other areas such as depression and high blood pressure [5] Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing medication-resistant seizures, highlighting the need for alternative treatment options like RF ablation therapy [2] - The OneRF® system offers a more efficient and precise approach for patients who do not respond to traditional medication, potentially reducing the need for multiple invasive surgeries [4]

Core Insights - NeuroOne Medical Technologies Corporation is focused on improving surgical care for patients with neurological disorders, particularly epilepsy, through innovative technology [1][5] - The company’s OneRF Ablation System is the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously, representing a significant advancement in epilepsy treatment [3][4] Company Overview - NeuroOne develops minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation for conditions such as epilepsy, Parkinson's disease, and chronic pain [5] - The OneRF system includes an electrode for brain activity monitoring and ablation, a temperature probe, and a radio frequency heat generator [3] Market Context - Over 50 million people globally are affected by epilepsy, with about one-third experiencing medication-resistant seizures, highlighting the need for alternative treatments like RF ablation therapy [2] - The OneRF platform has potential applications beyond epilepsy, including pain management and other neurological disorders [4][5]

Core Insights - NeuroOne Medical Technologies Corporation is focused on improving surgical care options for patients with neurological disorders, particularly epilepsy, through innovative technology [1][5] - The OneRF® Ablation System is a significant advancement in epilepsy treatment, being the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [3][4] Company Overview - NeuroOne is developing minimally invasive solutions for EEG recording, brain stimulation, and ablation for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5] - The company aims to enhance patient outcomes and reduce procedural costs while exploring applications in other areas such as depression and high blood pressure [5] Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing medication-resistant seizures, highlighting the need for alternative treatment options like RF ablation therapy [2] - The OneRF® system offers a more efficient and precise approach for patients who do not respond to traditional medication, potentially reducing the need for multiple invasive surgeries [4]

Core Viewpoint - NeuroOne Medical Technologies Corporation is advancing epilepsy treatment through its innovative OneRF Ablation System, which combines brain activity monitoring and radiofrequency ablation in a single device, aiming to improve patient outcomes and reduce the need for multiple surgeries [1][4][3]. Company Overview - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) focuses on developing minimally invasive and high-definition solutions for neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5]. - The company is exploring applications for its technology in various areas such as depression, mood disorders, and high blood pressure [5]. Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing seizures that do not respond to medication, highlighting the need for alternative treatment options like RF ablation therapy [2]. - The OneRF Ablation System is the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously, representing a significant advancement in the treatment of epilepsy [3].